Cite
HARVARD Citation
Gazzilli, M. et al. (2020). Three years' clinical practice of Radium-223 therapy in patients with symptomatic bone metastases from metastatic castrate-resistant prostate cancer. Nuclear medicine communications. 41 (4), p. . [Online].